MAIA Biotechnology, Inc.

90.5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient population CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action drug incorporating telomere targeting and immunogenicity, as a third-line (3L) therapy for patients with advanced non-small cell lung cancer (NSCLC).  Initial data from the THIO-101 Part C 3L studies1 show a disease control rate (DCR) of 90.5% (19 out of 21 patients) in the efficacy evaluable population who had at least one tumor scan after starting treatment.

globenewswire.com - 2026-07-08 09:45:00

90. 5% interim disease control rate (DCR) observed with combination therapy Initial Part C efficacy observations align with previously reported THIO-101 clinical activity despite a more heavily pre-treated patient population CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced positive initial efficacy data from its Phase 2 THIO-101 clinical trial expansion, Part C, evaluating its lead candidate, ateganosine, a dual mechanism of action drug incorporating telomere targeting and immunogenicity, as a third-line (3L) therapy for patients with advanced non-small cell lung cancer (NSCLC).

globenewswire.com - 2026-07-08 09:45:00

Part C domestic enrollment is underway at three clinical sites in the U.S. CHICAGO, June 25, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has completed international enrollment in Part C of its Phase 2 THIO-101 expansion trial evaluating its lead candidate, ateganosine, in advanced non-small cell lung cancer (NSCLC) patients receiving third line (3L) therapy. Ateganosine is an investigational dual-mechanism therapy targeting telomeres and immune activation in difficult-to-treat cancers.

globenewswire.com - 2026-06-25 08:08:00

Georgia's only National Cancer Institute (NCI)-designated Comprehensive Cancer Center; well recognized at the forefront of cancer innovation and discovery nationwide CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the third U.S. clinical site in its Phase 2 THIO-101 expansion trial, Winship Cancer Institute of Emory University (“Winship”), is activated and now enrolling patients. The trial studies MAIA's lead investigational telomere-targeting agent, ateganosine, as a third-line (3L) treatment for non-small cell lung cancer (NSCLC).

globenewswire.com - 2026-06-18 08:30:00

Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected $70 billion global non-small cell lung cancer market by 20301 CHICAGO, June 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc.

globenewswire.com - 2026-06-10 09:15:00

Additional data from MAIA's THIO-101 expansion may further support an accelerated approval filing with the FDA Potential breakthrough therapy holds substantial commercial opportunity in a projected $70 billion global non-small cell lung cancer market by 2030 1 CHICAGO, June 10, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has activated the second U.S. clinical site in its Phase 2 THIO-101 expansion trial at Central Alabama Research in Homewood, Alabama. The expansion part of THIO-101 evaluates MAIA's lead investigational therapy, ateganosine, a dual-action molecule incorporating telomere targeting and immunogenicity, as a third-line (3L) treatment for non-small cell lung cancer (NSCLC) in patients who have previously failed treatment with checkpoint inhibitors (CPIs) and chemotherapy.

globenewswire.com - 2026-06-10 09:15:00

MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer CHICAGO, June 04, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today provided a patient enrollment update for its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targeting therapy as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC).

globenewswire.com - 2026-06-04 09:45:00

MAIA's novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer

globenewswire.com - 2026-06-04 09:45:00

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA FDA-cleared IND updates detail latest efficacy data and enriched manufacturing protocols CHICAGO, June 03, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.

globenewswire.com - 2026-06-03 09:45:00

Additional data from THIO-101 trial expansion studies may further support a potential Accelerated Approval filing with FDA

globenewswire.com - 2026-06-03 09:45:00

CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that its founder and CEO Vlad Vitoc, M.D. and Director Stan V. Smith, Ph.D. have increased their ownership positions through open market purchases.

globenewswire.com - 2026-06-02 09:45:00

CHICAGO, June 02, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that its founder and CEO Vlad Vitoc, M. D. and Director Stan V. Smith, Ph.

globenewswire.com - 2026-06-02 09:45:00

CHICAGO, June 01, 2026 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, delivered a poster presentation on May 31, 2026, featuring the methodology and study design for its pivotal Phase 3 clinical trial (THIO-104) at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO 2026), being held May 29 – June 2, 2026, in MAIA's home city of Chicago, Illinois. THIO-104 evaluates the efficacy of MAIA's telomere targeting agent, ateganosine, administered in sequence with a checkpoint inhibitor (CPI) in third-line non-small cell lung cancer (NSCLC) patients resistant to CPIs and chemotherapy.

globenewswire.com - 2026-06-01 08:00:00

New York, May 18, 2026 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE: MAIA). The research summary below is from a report commissioned by MAIA Biotechnology, Inc. and produced by Diamond Equity Research.

globenewswire.com - 2026-05-18 08:00:00